JM Ye, PJ Doyle, MA Iglesias, DG Watson, … - Diabetes, 2001 - Am Diabetes Assoc Peroxisome proliferator—activated receptor (PPAR)-α agonists lower
circulating lipids, but the consequences for muscle lipid metabolism and insulin
sensitivity are not clear. We investigated whether PPAR-α activation ... Cited by 239 - Related articles - BL Direct - All 6 versions
M Guerre-Millo, P Gervois, E Raspe, L Madsen … - Journal of Biological Chemistry, 2000 - ASBMB Fibrates and glitazones are two classes of drugs currently used in the treatment
of dyslipidemia and insulin resistance (IR), respectively. Whereas glitazones
are insulin sensitizers acting via activation of the peroxisome ... Cited by 382 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org H Kim, M Haluzik, Z Asghar, D Yau, JW … - Diabetes, 2003 - Am Diabetes Assoc Abnormalities in insulin action are the characteristics of type 2 diabetes.
Dominant-negative muscle-specific IGF-I receptor (MKR) mice exhibit elevated
lipid levels at an early age and eventually develop type 2 diabetes. To ... Cited by 110 - Related articles - BL Direct - All 4 versions
CJ Chou, M Haluzik, C Gregory, KR Dietz, C … - Journal of Biological Chemistry, 2002 - ASBMB WY14,643 is a specific peroxisome proliferator-activated receptor α (PPARα)
agonist with strong hypolipidemic effects. Here we have examined the effect of
WY14,643 in the A-ZIP/F-1 mouse, a model of severe lipoatrophic diabetes. ... Cited by 103 - Related articles - BL Direct - All 4 versions
- ►psu.edu [PDF] M Guerre-Millo, C Rouault, P Poulain, J André … - Diabetes, 2001 - Am Diabetes Assoc Peroxisome proliferator–activated receptor (PPAR)-α controls the expression
of genes involved in lipid metabolism. PPAR-α furthermore participates to
maintain blood glucose during acute metabolic stress, as shown in ... Cited by 135 - Related articles - BL Direct - All 6 versions
- ►physiology.org A Minnich, N Tian, L Byan, G Bilder - American Journal of Physiology- Endocrinology And …, 2001 - Am Physiological Soc The proposed mechanism for the triglyceride (TG) lowering by fibrate drugs is
via activation of the peroxisome proliferator-activated receptor- (PPAR ). Here
we show that a PPAR agonist, ureido-fibrate-5 (UF-5), ~200-fold more potent ... Cited by 86 - Related articles - BL Direct - All 3 versions
EH Koh, MS Kim, JY Park, HS Kim, JY Youn, … - Diabetes, 2003 - Am Diabetes Assoc Lipid accumulation in nonadipose tissues is closely related to the development
of type 2 diabetes in obese subjects. We examined the potential preventive
effect of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ ... Cited by 103 - Related articles - BL Direct - All 6 versions
- ►physiology.org JM Ye, MA Iglesias, DG Watson, B Ellis, L … - American Journal of Physiology- Endocrinology And …, 2003 - Am Physiological Soc Peroxisome proliferator-activated receptor (PPAR) and PPAR agonists lower lipid
accumulation in muscle and liver by different mechanisms. We investigated
whether benefits could be achieved on insulin sensitivity and lipid ... Cited by 86 - Related articles - BL Direct - All 3 versions
M Kobayashi, Y Shigeta, Y Hirata, Y Omori, … - Diabetes Care, 1988 - Am Diabetes Assoc A randomized double-blind study was performed to examine the effect of
clofibrate on glucose tolerance in subjects with non-insulin-dependent diabetes
mellitus (NIDDM). Clofibrate (1.5 g/day) or placebo was administered to 70 ... Cited by 53 - Related articles - All 4 versions
HJ Lee, SS Choi, MK Park, YJ An, SY Seo, … - Biochemical and biophysical research communications, 2002 - Elsevier The effect of peroxisome proliferator-activated receptor (PPAR)-α activators on
the liver is well established, but the other effects on muscle and adipose
tissue about lipid metabolism and insulin sensitivity are not clear. We ... Cited by 78 - Related articles - BL Direct - All 6 versions
